FierceBiotech 2026-02-18 Blood from pediatricians yields potential new medicines for respiratory viruses
FierceBiotech 2026-02-18 Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal
FierceBiotech 2026-02-18 Sensei steps back from brink by finding Faeth and its phase 2-stage cancer drug
FierceBiotech 2026-02-18 Gut-focused Rasayana ingests gastrointestinal candidate in $36M licensing deal
FierceBiotech 2026-02-18 Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study
FierceBiotech 2026-02-18 Korsana crosses into crowded Alzheimer's field with $175M and anti-amyloid antibody
FierceBiotech 2026-02-18 Immunology CRO RoukenBio pens pact with AVS Bio for more predictable antibody development
FierceBiotech 2026-02-17 Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering
FierceBiotech 2026-02-17 Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push
FierceBiotech 2026-02-17 Novocure gets FDA nod for tumor-treating electric fields targeting pancreatic cancer
FierceBiotech 2026-02-17 Gilead’s latest synthetic lethal therapy comes via $1.5B deal with China’s Genhouse
FierceBiotech 2026-02-16 Biopharma funding to experience 'continued, albeit disciplined' recovery in 2026: PitchBook
FierceBiotech 2026-02-14 'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments